Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Tumours (NETs)”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Testing effectiveness (Phase 2)Study completedNCT02305810
What this trial is testing

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

Who this might be right for
Pancreatic Neuroendocrine Tumour Metastatic
European Institute of Oncology 54
Not applicableStudy completedNCT01879657
What this trial is testing

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Who this might be right for
Neuroendocrine Carcinoma
Radio Isotope Therapy of America 169
Large-scale testing (Phase 3)Active Not RecruitingNCT05459844
What this trial is testing

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Sinotau Pharmaceutical Group 196
Not applicableStudy completedNCT03017690
What this trial is testing

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Ipsen 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT03891784
What this trial is testing

Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

Who this might be right for
Advanced Digestive System Neuroendocrine NeoplasmDigestive System Neuroendocrine TumorForegut Neuroendocrine Tumor+6 more
University of Washington 20
Early research (Phase 1)Study completedNCT01590199
What this trial is testing

Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 18
Not applicableApproved For MarketingNCT04334837
What this trial is testing

Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)

Who this might be right for
Neuroendocrine Tumors
Curium US LLC
Testing effectiveness (Phase 2)Active Not RecruitingNCT04711135
What this trial is testing

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Who this might be right for
Gastroenteropancreatic Neuroendocrine TumorsPheochromocytomaParaganglioma
Advanced Accelerator Applications 11
Testing effectiveness (Phase 2)Ended earlyNCT00958841
What this trial is testing

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Who this might be right for
Pancreatic NeoplasmPituitary NeoplasmNelson Syndrome+1 more
Novartis Pharmaceuticals 118
Testing effectiveness (Phase 2)Study completedNCT04362436
What this trial is testing

TheraSphere Selective Internal Radiation Therapy (SIRT) as Treatment for Neuroendocrine Tumours With Liver Mets

Who this might be right for
Neuroendocrine TumorsLiver Metastases
Imperial College London 24
Large-scale testing (Phase 3)Study completedNCT03136328
What this trial is testing

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Who this might be right for
Neuroendocrine Tumors
Montefiore Medical Center 11
Not applicableNot Yet RecruitingNCT06607198
What this trial is testing

Clinical-pathological Evaluation of Pit-NETs

Who this might be right for
PituitaryCancerNeuroendocrine Tumors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 940
Not applicableEnded earlyNCT05922579
What this trial is testing

Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

Who this might be right for
Neuroendocrine Tumors
Ipsen 191
Not applicableLooking for participantsNCT04282083
What this trial is testing

Protocol ITANET - Registry

Who this might be right for
Gastro-entero Pancreatic Neuroendocrine Tumors
Italian Association Neuroendocrine Tumors 3,600
Testing effectiveness (Phase 2)Study completedNCT02575300
What this trial is testing

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Who this might be right for
Carcinoid TumorsPancreatic NET
H. Lee Moffitt Cancer Center and Research Institute 20
Not applicableStudy completedNCT04649580
What this trial is testing

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

Who this might be right for
Neuroendocrine Tumours (NET)
Ipsen 80
Testing effectiveness (Phase 2)Looking for participantsNCT05554003
What this trial is testing

Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

Who this might be right for
Neuroendocrine TumorsFrailtyChemotherapy Effect
European Institute of Oncology 46
Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Post-approval studies (Phase 4)Study completedNCT01595009
What this trial is testing

An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1)

Who this might be right for
Neuroendocrine Tumors
Novartis Pharmaceuticals 246
Early research (Phase 1)WithdrawnNCT01864070
What this trial is testing

Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease

Who this might be right for
Liver Cancer
M.D. Anderson Cancer Center
Next Page